Close Menu

QuantumDx

The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.

The firm also announced the appointment of new board members as it heads toward commercialization of a portable MDx platform.

The test will be developed in Global Good labs and ported onto QuantuMDx's handheld molecular platform.

Q-POC

The funding will be used to further develop a 20-minute tuberculosis detection assay and drug susceptibility test using the firm's handheld Q-POC microfluidic PCR system.

QuantuMDx says its low-cost, handheld device will be able to quickly diagnose patients, as the Guardian reports.

QuantuMDx will use Scienion's ultra-low-volume liquid handling technologies in its Q-Poc handheld molecular diagnostic device.

The California Institute of Technology has been awarded

NEW YORK (GenomeWeb) – The Foundation for Innovative New Diagnostics is collaborating with multiple firms to accelerate the development of low-cost molecular diagnostics for tuberculosis and drug resistance determination, the non-profit organization said today.

NEW YORK (GenomeWeb) – QuantuMDx, a Newcastle, UK-based molecular diagnostics company, last week announced that it had successfully completed the development of its Q-POC handheld testing device.

Pages

The American Prospect writes that the pilot program to test the DNA of migrants could lead to more family separations.

An international commission is to develop a report on how researchers, clinicians, and regulators should evaluate the clinical applications of human germline genome editing.

The US Department of Agriculture presents a new blueprint for animal genomic research.

In Genome Research this week: repetitive element deletion linked to altered methylation and more in form of muscular dystrophy; human contamination in draft bacterial and archaeal genomes; and more.